Optimizing Treatment in Low-risk MDS: Current and Future Standard of Care in Patients with Non-deletion 5q

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: June 25, 2018
Expiration Date: June 25, 2019

Expected time to complete this activity as designed: 60 minutes

There are no fees for participating in or receiving credit for this online activity.

Program Overview

When decisions are made on MDS treatment, prognostic risk is determined using many patient-specific factors. With MDS therapies continuing to evolve, oncology nurses are challenged to stay up-to-date with recent treatment advances in which therapies are tailored based on patients being classified as having high- or low-risk disease. To appropriately manage MDS, patients must understand the impact of their level of risk on their treatment.

Oncology nurses are at the forefront of providing supportive care to patients when new therapies and treatment plans are initiated. They must balance potential benefits with tolerability and risks for side effects. In this activity, Dr. Olatoyosi Odenike discusses treatment strategies for low-risk MDS and evaluates how recent advances and emerging options are impacting the current standard of care. Dr. Eunice S. Wang summarizes strategies for the appropriate use of several different types of drug therapies and discusses clinical trial data that will help guide the management of high-risk MDS patients.

Target Audience

This activity is designed for nurses in the community setting who provide care to patients with myelodysplastic syndromes.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Summarize the treatment goals and practice challenges associated with low-risk MDS patients with non-del(5q)
  • Outline the treatment approach and current standard of care in low-risk MDS with non-del(5q)
  • Summarize strategies for optimizing patient selection and treatment in high-risk MDS
  • Describe recent advances and future directions throughout the spectrum of the disease

Agenda

Optimizing Treatment in Low-risk MDS: Current and Future Standard of Care in Patients with Non-deletion 5q – Olatoyosi Odenike, MD

Optimizing Outcomes in High-risk MDS: Current and Emerging Standards of Care – Eunice S. Wang, MD

Instructions for Participation and Credit

This activity is eligible for credit through October 31, 2019. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CNE may be printed immediately after successfully completing the post-test and activity evaluation.

Faculty Biographies

Olatoyosi Odenike, MD
Associate Professor of Medicine
University of Chicago
Chicago, Illinois

Dr. Olatoyosi (Toyosi) Odenike received her pre-medical training at the University of Ife, Nigeria, and her medical degree from the University of Ibadan, Nigeria. She completed her residency training in internal medicine and pediatrics at the University of Illinois and her hematology/oncology fellowship training at the University of Chicago. She is an Associate Professor of Medicine at the University of Chicago.

Dr. Odenike’s clinical research and medical practice is focused on myeloid malignancies, including myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPNs), and acute myeloid leukemia (AML). She has a particular interest in new drug development in these diseases and has authored/co-authored several early phase trials and manuscripts focused on this patient population. Dr. Odenike currently serves as Co-Director of the University of Chicago Phase II Personalized Care Consortium and is a member of the Alliance Leukemia Core Committee. She has served on various professional committees including chair of educational programs focused on MDS and MPNs for the American Society of Clinical Oncology (ASCO) and the American Society of Hematology (ASH). She is also a member of the ASH Consult a Colleague Program and the Aplastic Anemia/MDS International Foundation Medical Advisory Board. In addition, Dr. Odenike is a standing member of the Molecular and Cellular Hematology NIH Study Section, and serves on the Medical Oncology Board Examination Committee of the American Board of Internal Medicine. She is a past recipient of an ASCO Career Development Award.

Eunice S. Wang, MD
Chief, Clinical Leukemia Service
Professor, Department of Medicine
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Dr. Eunice Wang earned her medical degree from the Keck (University of Southern California) School of Medicine. She completed her internship and residency in internal medicine at Yale-New Haven Hospital, followed by clinical and research fellowships in hematology-oncology at Memorial Sloan Kettering Cancer Center in New York. She is Chief of the Leukemia Service and Professor of Oncology in the Department of Medicine at Roswell Park Comprehensive Cancer Center, Buffalo, New York. She is also an Associate Professor in the Department of Medicine, School of Medicine of Biomedical Sciences at the State University of New York at Buffalo (SUNY-UB).

Dr. Wang is a member of several professional organizations including the American Society of Hematology and the American Society of Clinical Oncology. She serves on the National Comprehensive Cancer Network (NCCN) Clinical Practice treatment guidelines panels for acute myeloid and acute lymphocytic leukemia. She is a prior recipient of a NIH Cancer Clinical Investigator Team Leadership Award (CCITLA) and a Mentored Research Scholar award from the American Cancer Society. Dr. Wang has authored/co-authored more than 90 peer-reviewed articles in the field of hematological malignancies. She maintains an active clinical practice with a portfolio of early phase clinical trials in acute leukemias and myeloid malignancies. She also leads a translational laboratory focused on preclinical studies of novel agents targeting the marrow microenvironment and immune responses.

Accreditation

MediCom NURSING CREDIT
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 18-040-088

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. Toyosi Odenike has received honoraria as a consultant from AbbVie Inc., Baxalta, CTI BioPharma Corp., DAVA Oncology, Jazz Pharmaceuticals plc, and Pfizer Inc. She has received grant support related to research activities from AbbVie, Agios, Astex Pharmaceuticals, Baxalta, Celgene Corporation, CTI BioPharma, Incyte Corporation, Janssen Pharmaceuticals, Inc., and NS Pharma, Inc. She has received an honorarium as a committee member with the American Board of Internal Medicine (ABIM).

Dr. Eunice Wang has received honoraria related to formal advisory activities from AbbVie Inc., Amgen Inc., Arog Pharmaceuticals, Inc., ImmunoGen, Inc., and Pfizer Inc., as well as speakers’ bureau activities from Jazz Pharmaceuticals plc and Novartis AG.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Kristin Burke, Project Manager, Keith D’Oria, Medical Writer, and Joan Meyer, RN, MHA, Executive Director, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at lisa@medicaled.com.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Onconova Therapeutics Inc.

©2018 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.